PAH at a glance

PAH leads to elevated blood pressure in the pulmonary arteries, resulting in heart and lung damage and a decreased lifespan for patients.2

PAH

WHO GROUP 1* Infographic showing that over 40,000 patients are treated in the US and have an approximately 75% 3-year survival rate.

*WHO Group 1 refers to PAH, which is caused when the arteries in the lungs become narrowed, thickened, or stiff. As a result, the right side of the heart must work harder to push blood through these arteries.2

 

Focusing on the potential of inhaled treprostinil

Treprostinil is one of the most widely used prostacyclin analogs for the treatment of PAH. Clinical benefits of prostacyclin therapy are well-established and include reduced symptoms of PAH , improved prognostic measures of risk, such as exercise capacity and functional class, and delayed disease progression.4

When inhaled, prostacyclin analogs like treprostinil have the potential to offer substantial benefits over other methods of administration, potentially reducing systemic side effects and providing faster onset than oral formulations.5

References:

  1. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2023;44(15):1312. doi:10.1093/eurheartj/ehad005
  2. Hendriks PM, Staal DP, van de Groep LD, et al. The evolution of survival of pulmonary arterial hypertension over 15 years. Pulm Circ. 2022;12(4):e12137. Published 2022 Oct 1. doi:10.1002/pul2.12137
  3. Kacprzak A, Tomkowski W, Szturmowicz M. Pulmonary Hypertension in the Course of Interstitial Lung Diseases-A Personalised Approach Is Needed to Identify a Dominant Cause and Provide an Effective Therapy. Diagnostics (Basel). 2023;13(14):2354. Published 2023 Jul 13. doi:10.3390/diagnostics13142354
  4. Mitchell JA, Ahmetaj-Shala B, Kirkby NS, et al. Role of prostacyclin in pulmonary hypertension. Glob Cardiol Sci Pract. 2014;2014(4):382-393. Published 2014 Dec 31. doi:10.5339/gcsp.2014.53
  5. Harrison W. Farber, Wendy Gin-Sing. Practical considerations for therapies targeting the prostacyclin pathway. European Respiratory Review Dec 2016, 25 (142) 418-430; DOI:10.1183/16000617.0083-2016